Background Trastuzumab emtansine is the current standard treatment for patients with
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …

Background An improvement in progression-free survival was shown with trastuzumab
deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast …

Background Among breast cancers without human epidermal growth factor receptor 2
(HER2) amplification, overexpression, or both, a large proportion express low levels of …

Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate
composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a …

Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2
(HER2)–targeted monoclonal antibodies, and trastuzumab emtansine (T-DM1) is an …

Background HER2-positive metastatic breast cancer is incurable and new treatments are
needed. Addition of atezolizumab to trastuzumab emtansine might potentiate anticancer …

Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and …

Purpose Our phase IIa study characterized the safety and efficacy of two human epidermal
growth factor receptor 2 (HER2)–targeted agents, trastuzumab emtansine (T-DM1) and …

Abstract On February 22, 2013, the FDA licensed ado-trastuzumab emtansine (Kadcyla;
Genentech, Inc.) for use as a single agent for the treatment of patients with human epidermal …

Background The antibody–drug conjugate trastuzumab emtansine is indicated for the
treatment of patients with HER2-positive metastatic breast cancer previously treated with …